Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Repligen Corp (RGEN)

Repligen Corp (RGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,285,318
  • Shares Outstanding, K 56,149
  • Annual Sales, $ 634,440 K
  • Annual Income, $ -25,510 K
  • EBIT $ -32 M
  • EBITDA $ 53 M
  • 60-Month Beta 1.27
  • Price/Sales 12.81
  • Price/Cash Flow 46.59
  • Price/Book 4.11

Options Overview Details

View History
  • Implied Volatility 55.02% ( -0.03%)
  • Historical Volatility 73.97%
  • IV Percentile 74%
  • IV Rank 42.94%
  • IV High 84.92% on 04/07/25
  • IV Low 32.53% on 05/17/24
  • Put/Call Vol Ratio 0.21
  • Today's Volume 123
  • Volume Avg (30-Day) 314
  • Put/Call OI Ratio 5.44
  • Today's Open Interest 8,614
  • Open Int (30-Day) 7,903

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.35
  • Number of Estimates 6
  • High Estimate 0.38
  • Low Estimate 0.32
  • Prior Year 0.28
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
102.96 +40.59%
on 04/07/25
148.94 -2.81%
on 04/23/25
+2.80 (+1.97%)
since 03/25/25
3-Month
102.96 +40.59%
on 04/07/25
182.52 -20.69%
on 01/28/25
-21.14 (-12.74%)
since 01/24/25
52-Week
102.96 +40.59%
on 04/07/25
182.52 -20.69%
on 01/28/25
-20.91 (-12.62%)
since 04/25/24

Most Recent Stories

More News
3 Healthcare Stocks That Concern Us

3 Healthcare Stocks That Concern Us

MYGN : 7.42 (+0.68%)
RGEN : 144.75 (-0.33%)
IQV : 150.28 (-0.27%)
Repligen to Report First Quarter 2025 Financial Results

RGEN : 144.75 (-0.33%)
Repligen (RGEN): Buy, Sell, or Hold Post Q4 Earnings?

Repligen (RGEN): Buy, Sell, or Hold Post Q4 Earnings?

MSFT : 391.85 (+1.17%)
RGEN : 144.75 (-0.33%)
Repligen Appoints Jacob Johnson As Vice President Investor Relations

RGEN : 144.75 (-0.33%)
Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks

Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks

FTRE : 5.92 (+1.02%)
UFPT : 206.80 (-0.04%)
AZTA : 26.73 (-1.47%)
RGEN : 144.75 (-0.33%)
IQV : 150.28 (-0.27%)
Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers

Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers

MEDP : 298.55 (-1.43%)
FTRE : 5.92 (+1.02%)
AZTA : 26.73 (-1.47%)
RGEN : 144.75 (-0.33%)
CRL : 114.66 (-0.95%)
Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks

Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks

FTRE : 5.92 (+1.02%)
TECH : 50.24 (-1.06%)
PACB : 1.0900 (-4.39%)
RGEN : 144.75 (-0.33%)
MTD : 1,061.79 (-1.23%)
Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks

Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks

FTRE : 5.92 (+1.02%)
UFPT : 206.80 (-0.04%)
AZTA : 26.73 (-1.47%)
RGEN : 144.75 (-0.33%)
WST : 214.55 (+1.88%)
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack

A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack

FTRE : 5.92 (+1.02%)
MEDP : 298.55 (-1.43%)
RGEN : 144.75 (-0.33%)
AZTA : 26.73 (-1.47%)
IQV : 150.28 (-0.27%)
3 Small-Cap Stocks Skating on Thin Ice

3 Small-Cap Stocks Skating on Thin Ice

RGEN : 144.75 (-0.33%)
ICUI : 135.66 (-1.09%)
DAY : 57.81 (+0.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Repligen Corporation is a leading provider of advanced bioprocessing technologies and solutions used by large biopharmaceutical companies and contract manufacturing organizations for manufacturing biologic drugs, such as monoclonal antibodies (mAbs) and gene therapies. Repligen earns revenues from the...

See More

Key Turning Points

3rd Resistance Point 151.90
2nd Resistance Point 148.93
1st Resistance Point 146.84
Last Price 144.75
1st Support Level 141.77
2nd Support Level 138.80
3rd Support Level 136.71

See More

52-Week High 182.52
Fibonacci 61.8% 152.13
Last Price 144.75
Fibonacci 50% 142.74
Fibonacci 38.2% 133.35
52-Week Low 102.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar